Author Details

Chan, Steve

  • Vol 11, No 1 (2015) - Onkologia na świecie
    Subcutaneous trastuzumab (Herceptin®): A UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer
    Abstract  PDF (Polish)  HTML (Polish)

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl